IRWD
Price
$3.26
Change
+$0.05 (+1.56%)
Updated
Dec 24 closing price
Capitalization
530.33M
48 days until earnings call
Intraday BUY SELL Signals
PAHC
Price
$37.74
Change
+$0.35 (+0.94%)
Updated
Dec 24 closing price
Capitalization
1.53B
47 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IRWD vs PAHC

Header iconIRWD vs PAHC Comparison
Open Charts IRWD vs PAHCBanner chart's image
Ironwood Pharmaceuticals
Price$3.26
Change+$0.05 (+1.56%)
Volume$583.97K
Capitalization530.33M
Phibro Animal Health
Price$37.74
Change+$0.35 (+0.94%)
Volume$131.61K
Capitalization1.53B
IRWD vs PAHC Comparison Chart in %
IRWD
Daily Signal:
Gain/Loss:
PAHC
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
IRWD vs. PAHC commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IRWD is a Hold and PAHC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (IRWD: $3.26 vs. PAHC: $37.74)
Brand notoriety: IRWD and PAHC are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: IRWD: 21% vs. PAHC: 42%
Market capitalization -- IRWD: $530.33M vs. PAHC: $1.53B
IRWD [@Pharmaceuticals: Generic] is valued at $530.33M. PAHC’s [@Pharmaceuticals: Generic] market capitalization is $1.53B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IRWD’s FA Score shows that 0 FA rating(s) are green whilePAHC’s FA Score has 1 green FA rating(s).

  • IRWD’s FA Score: 0 green, 5 red.
  • PAHC’s FA Score: 1 green, 4 red.
According to our system of comparison, PAHC is a better buy in the long-term than IRWD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IRWD’s TA Score shows that 4 TA indicator(s) are bullish while PAHC’s TA Score has 3 bullish TA indicator(s).

  • IRWD’s TA Score: 4 bullish, 4 bearish.
  • PAHC’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, IRWD is a better buy in the short-term than PAHC.

Price Growth

IRWD (@Pharmaceuticals: Generic) experienced а -3.26% price change this week, while PAHC (@Pharmaceuticals: Generic) price change was -7.04% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.58%. For the same industry, the average monthly price growth was +8.11%, and the average quarterly price growth was +22.96%.

Reported Earning Dates

IRWD is expected to report earnings on Feb 12, 2026.

PAHC is expected to report earnings on Feb 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.58% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PAHC($1.53B) has a higher market cap than IRWD($530M). PAHC has higher P/E ratio than IRWD: PAHC (22.60) vs IRWD (18.11). PAHC YTD gains are higher at: 82.106 vs. IRWD (-26.411). PAHC has higher annual earnings (EBITDA): 181M vs. IRWD (129M). IRWD has more cash in the bank: 140M vs. PAHC (85.3M). IRWD has less debt than PAHC: IRWD (598M) vs PAHC (785M). PAHC has higher revenues than IRWD: PAHC (1.4B) vs IRWD (339M).
IRWDPAHCIRWD / PAHC
Capitalization530M1.53B35%
EBITDA129M181M71%
Gain YTD-26.41182.106-32%
P/E Ratio18.1122.6080%
Revenue339M1.4B24%
Total Cash140M85.3M164%
Total Debt598M785M76%
FUNDAMENTALS RATINGS
IRWD vs PAHC: Fundamental Ratings
IRWD
PAHC
OUTLOOK RATING
1..100
6458
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
27
Undervalued
PROFIT vs RISK RATING
1..100
10040
SMR RATING
1..100
10040
PRICE GROWTH RATING
1..100
3545
P/E GROWTH RATING
1..100
10095
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAHC's Valuation (27) in the Pharmaceuticals Major industry is in the same range as IRWD (58) in the Pharmaceuticals Other industry. This means that PAHC’s stock grew similarly to IRWD’s over the last 12 months.

PAHC's Profit vs Risk Rating (40) in the Pharmaceuticals Major industry is somewhat better than the same rating for IRWD (100) in the Pharmaceuticals Other industry. This means that PAHC’s stock grew somewhat faster than IRWD’s over the last 12 months.

PAHC's SMR Rating (40) in the Pharmaceuticals Major industry is somewhat better than the same rating for IRWD (100) in the Pharmaceuticals Other industry. This means that PAHC’s stock grew somewhat faster than IRWD’s over the last 12 months.

IRWD's Price Growth Rating (35) in the Pharmaceuticals Other industry is in the same range as PAHC (45) in the Pharmaceuticals Major industry. This means that IRWD’s stock grew similarly to PAHC’s over the last 12 months.

PAHC's P/E Growth Rating (95) in the Pharmaceuticals Major industry is in the same range as IRWD (100) in the Pharmaceuticals Other industry. This means that PAHC’s stock grew similarly to IRWD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IRWDPAHC
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 3 days ago
66%
MACD
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 7 days ago
72%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 16 days ago
67%
Bullish Trend 15 days ago
74%
Declines
ODDS (%)
Bearish Trend 7 days ago
79%
Bearish Trend 7 days ago
71%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
IRWD
Daily Signal:
Gain/Loss:
PAHC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VSPVX453.911.98
+0.44%
Vanguard S&P 500 Value Index Instl
VLAIX35.460.08
+0.23%
Value Line Asset Allocation Instl
FEVAX23.460.05
+0.21%
First Eagle US A
FRSLX25.580.05
+0.20%
Nuveen Small/Mid Cap Growth Opp A
EAMAX20.290.04
+0.20%
Lord Abbett Emerging Markets Equity A

IRWD and

Correlation & Price change

A.I.dvisor tells us that IRWD and ACET have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IRWD and ACET's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IRWD
1D Price
Change %
IRWD100%
+1.56%
ACET - IRWD
30%
Poorly correlated
+6.85%
PRGO - IRWD
29%
Poorly correlated
+0.51%
AMRX - IRWD
26%
Poorly correlated
+0.23%
ELAN - IRWD
24%
Poorly correlated
+0.72%
PAHC - IRWD
24%
Poorly correlated
+0.94%
More

PAHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with ELAN. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAHC
1D Price
Change %
PAHC100%
+0.94%
ELAN - PAHC
41%
Loosely correlated
+0.72%
AMRX - PAHC
41%
Loosely correlated
+0.23%
ZTS - PAHC
37%
Loosely correlated
+1.58%
PBH - PAHC
37%
Loosely correlated
+0.18%
VTRS - PAHC
33%
Poorly correlated
+1.83%
More